Terms of use

These Terms of Use (“Terms”) govern your access to and use of the website operated by Syremis Therapeutics Ltd. (“Syremis”, “we”, “us”, or “our”) (the “Site”). By accessing or using the Site, you agree to be bound by these Terms and all applicable laws and regulations. If you do not agree, you must not use the Site.

PURPOSE OF THE SITE

The Site is intended to provide general, informational content about Syremis, its research activities, and related corporate matters. The Site is not intended to provide medical advice, clinical trial enrollment services, or patient-specific guidance.

NO MEDICAL ADVICE

Any medical, scientific, or product-related information provided on the Site is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare professional regarding any medical condition.

NO WARRANTY

The Site and its content are provided on an “as is” and “as available” basis. To the fullest extent permitted by law, Syremis disclaims all warranties, express or implied, including warranties of accuracy, completeness, merchantability, fitness for a particular purpose, and non-infringement.

LIMITATION OF LIABILITY

To the maximum extent permitted by law, Syremis shall not be liable for any direct, indirect, incidental, consequential, special, or punitive damages arising out of or related to your use of, or inability to use, the Site, even if Syremis has been advised of the possibility of such damages.

USER CONDUCT

You agree not to:

  • Use the Site for any unlawful purpose;
  • Interfere with the operation or security of the Site;
  • Introduce malware, viruses, or harmful code;
  • Attempt to gain unauthorized access to systems or data;
  • Scrape, copy, or exploit Site content without authorization.

INTELLECTUAL PROPERTY

All content on the Site, including text, graphics, logos, trademarks, and software, is owned by or licensed to Syremis and is protected by intellectual property laws. No rights or licenses are granted except for limited personal, non-commercial use.

Copyright © 2009 Syremis Therapeutics. All rights reserved.

THIRD-PARTY LINKS

The Site may contain links to third-party websites. Syremis does not control or endorse such sites and is not responsible for their content, policies, or practices.

SUBMISSIONS

Any non-personal, non-confidential information submitted through the Site (excluding job applications and legally required safety reports) may be used by Syremis without restriction.

ACCESSIBILITY

Syremis is committed to making the Site accessible and will make reasonable efforts to address accessibility issues. Users experiencing difficulties may contact info@syremis.com

MODIFICATIONS TO THE SITE

Syremis may modify, suspend, or discontinue any aspect of the Site at any time without notice.

GOVERNING LAW AND JURISDICTION

These Terms shall be governed by and construed in accordance with the laws of the State of Israel, without regard to conflict of law principles. Exclusive jurisdiction shall lie with the competent courts located in Tel Aviv, Israel.

SEVERABILITY

If any provision of these Terms is held invalid or unenforceable, the remaining provisions shall remain in full force and effect.

ENTIRE AGREEMENT

These Terms constitute the entire agreement between you and Syremis regarding use of the Site.

CONTACT

For questions regarding these Terms, please contact info@syremis.com

Reid Huber PhD
Partner, Third Rock Ventures

Reid Huber joined Third Rock in 2018 as a Partner, bringing more than 25 years of leadership and experience to the role. He focuses on the formation, development, and strategy of Third Rock’s portfolio companies. Reid served as Interim CEO of MOMA Therapeutics until the appointment of Dr. Asit Parikh in Spring of 2021, of Rapport Therapeutics until the appointment of Abe Ceesay in the Spring of 2023, and of Merida Biosciences until the appointment of Adam Townsend in the Spring of 2025.


Reid joined TRV from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the company’s research and early development activities. Before joining Incyte, Reid held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1998 to 2002.


He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes 
of Health.


Reid is a board director at Rapport Therapeutics, Merida Biosciences, Terremoto, Synnovation Therapeutics, MOMA Therapeutics, Asher Biotherapeutics, and a board observer at insitro.